Prof G Markets
Scott & Ed on U.S.-EU tariffs, BYD cuts, OnlyFans' sale, and Damodaran on markets since Liberation Day.
Scott & Ed on U.S.-EU tariffs, BYD cuts, OnlyFans' sale, and Damodaran on markets since Liberation Day.
Showing1to20of424results
A political podcast tackling major issues with humor and a pragmatic middle ground.
Scott & Ed on the record $6.6 trillion tariff sell-off, its impact on earnings, and advice for investors.
Scott & Tarlov on Massie's defeat, the Texas Senate runoff, the Dems' 2024 autopsy, and Colbert signing off.
Scott Galloway answers listener questions on business, careers, tech, and life advice.
Scott Galloway and Ed Elson break down the biggest stories in business and markets.
A political podcast tackling major issues with humor and a pragmatic middle ground.
Kara and Scott unpack Anthropics IPO, political scandals, Blue Origins setback, and Jay Shettys big deal.
Scott Galloway and Ed Elson discuss global risks, markets, and AI with Prof. Aswath Damodaran.
Kara and Scott unpack Murdoch’s Vox deal, SpaceX’s IPO, Bezos, Cuban, Trump, and Nvidia earnings.
Scott Galloway answers listener questions on business, careers, tech, and life advice.
Scott & Ed live in Miami on Florida's tax haven model and why crypto is lagging despite soft regulation.
Scott & Tarlov on Iran's ceasefire, Fetterman's party switch, MAGA fractures, and a White House AI rethink.
Scott Galloway and Ed Elson break down the biggest stories in business and markets.
Scott Galloway and Ed Elson break down the biggest stories in business and markets.
Ed & guests on why high earners live paycheck to paycheck, lifestyle inflation, and real financial security.
Ed & guests on why high earners live paycheck to paycheck, lifestyle inflation, and real financial security.
Scott & Tarlov on Iran's ceasefire, Fetterman's party switch, MAGA fractures, and a White House AI rethink.
Scott & Tarlov on Iran's ceasefire, Fetterman's party switch, MAGA fractures, and a White House AI rethink.
Eli Lilly CEO David Ricks on GLP-1 drugs, obesity, healthcare costs, addiction, and AI in drug discovery.
Eli Lilly CEO David Ricks on GLP-1 drugs, obesity, healthcare costs, addiction, and AI in drug discovery.
Showing1to20of424results